Bolus-only versus bolus plus continuous infusion hydromorphone for refractory cancer pain: a prospective, multicenter, randomized noninferiority trial
Supportive Care in Cancer · 2026-11 · 34 (11)
DOI: 10.1007/s00520-026-11323-4 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift Supportive Care in Cancer, online erschienen am 22.10.2026. Verfasst von Zhe Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Medicine, College of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Analgesics, Opioid, Cancer Pain, Hydromorphone, Intractable Pain. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction
Refractory cancer pain (RCP) remains difficult to manage despite guideline-based therapy. Patient-controlled intravenous analgesia (PCIA) is increasingly used, yet the optimal administration mode remains unclear.
Methods
In this prospective, multicenter, randomized, non-inferiority trial, patients with refractory cancer pain were enrolled between December 1, 2018, and August 31, 2022, and randomly assigned to either a bolus-only PCIA group (Group B) or a bolus plus continuous infusion group (Group BC). Pain intensity was assessed using the Numerical Rating Scale (NRS). The primary endpoint was the pain relief rate at 72 h after PCIA initiation, defined as the proportion of patients achieving a ≥ 50% reduction in resting pain intensity from baseline. Non-inferiority was evaluated using the 90% confidence interval (CI) for the between-group difference, with a predefined non-inferiority margin of − 10%.
Results
A total of 226 patients were randomized. with 104 assigned to Group B and 111 to Group BC. Both groups showed significant reductions in resting NRS scores and breakthrough cancer pain (BTcP) NRS scores from T1 to T6 compared with baseline (all P < 0.05). At 72 h, the pain relief rate was 89.4% in Group B and 94.2% in Group BC. The between-group difference yielded a 90% CI of − 11.2% to 1.1%, which crossed the predefined non-inferiority margin. Therefore, non-inferiority of Group B compared with Group BC was not demonstrated. The incidence of PCIA-related adverse events was comparable between the two groups.
Conclusion
Non-inferiority of bolus-only PCIA compared with bolus plus continuous infusion was not established. Nevertheless, both PCIA administration modes provided effective analgesia and demonstrated favorable safety profiles in patients with refractory cancer pain. Clinical trial registration Chinese Clinical Trial Registry, ChiCTR1800020014. Registered 19 November 2018, https://www.chictr.org.cn/showprojEN.html?proj=32731
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pain Medicine, College of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China.
- Department of Pain Medicine, Affiliated Hospital of Medical School, Jinling Hospital, Nanjing University, Nanjing, China.
- Department of Pain Medicine, Hang Zhou Red Cross Hospital, Hangzhou, China.
- Department of Rare Cancer & Head and Neck Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy…
- Department of Pain Medicine, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Medical Oncology, The First People's Hospital of Linping District, Hangzhou, Zhejiang Province, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yan, Z., Fu, Y., Jin, Y., Zhao, W., Gong, L., Xie, G., Zhou, L., Tian, D., & Feng, Z. (2026). Bolus-only versus bolus plus continuous infusion hydromorphone for refractory cancer pain: a prospective, multicenter, randomized noninferiority trial. Supportive Care in Cancer, 34(11). https://doi.org/10.1007/s00520-026-11323-4
Vancouver
Yan Z, Fu Y, Jin Y, Zhao W, Gong L, Xie G, et al. Bolus-only versus bolus plus continuous infusion hydromorphone for refractory cancer pain: a prospective, multicenter, randomized noninferiority trial. Supportive Care in Cancer. 2026;34(11). doi:10.1007/s00520-026-11323-4
BibTeX
@article{Yan2026,
author = {Yan, Zhe and Fu, Yanbin and Jin, Yi and Zhao, Wensheng and Gong, Liyan and Xie, Guanglun and Zhou, Li and Tian, Demin and Feng, Zhiying},
title = {Bolus-only versus bolus plus continuous infusion hydromorphone for refractory cancer pain: a prospective, multicenter, randomized noninferiority trial},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {11},
doi = {10.1007/s00520-026-11323-4}
}
EUVIMED